Karyopharm Therapeutics Inc. 8-K

What Happened

• On July 13, 2026 the Board of Karyopharm Therapeutics, following its Compensation Committee’s recommendation, implemented the "2026 Leadership Cash Retention Program" and filed the related Form 8-K on July 17, 2026. The program replaces previously guaranteed amounts under the Company’s 2026 Annual Bonus Plan and provides lump‑sum cash retention awards to key executives.
• Award amounts are: Richard Paulson (President & CEO) $1,725,000; Stuart Poulton (EVP, Chief Development Officer) $640,000; Dr. Reshma Rangwala (EVP, Chief Medical Officer & Head of Research) $725,000; Lori Macomber (EVP, Chief Financial Officer & Treasurer) $625,000.

Key Details

• Total awarded to the four named executives: $3,715,000.
• Awards may be subject to repayment if the recipient’s employment ends for reasons other than termination by the Company without cause, termination by the participant for good reason, or death/permanent disability, and only if such termination occurs before the earlier of (i) 12 months after payment or (ii) 30 days after a qualifying corporate event.
• Payments under this program will reduce amounts otherwise payable under previously agreed severance arrangements.

Why It Matters

• The program is designed to retain senior management through an expected period of “meaningful catalysts,” so investors should note the company is prioritizing leadership continuity.
• It creates a near‑term cash outflow (lump‑sum payments) and modifies how 2026 compensation is delivered—replacing guaranteed bonus amounts with retention awards.
• The repayment/clawback conditions and the offset against severance affect the net economic cost and potential recovery if executives leave under certain circumstances. No change in executive roles or departures was reported in this filing.